Biotech Sector Weekly Rewind
BOSTON (
) -- Adam Feuerstein's take on the biotech week that ended Nov. 12, 2010:
The week's best-performing stocks in the sector:
Aastrom Biosciences
(ASTM)
(+48%),
AspenBio Pharma
(APPY)
(+32%),
Bionovo
(BNVO)
(28%),
Vermillion
(VRML) - Get Vermillion Inc. Report
(+26%) and
TheStreet Recommends
Genomic Health
(GHDX) - Get Genomic Health, Inc. Report
(+20%).
Is it any coincidence that Aastrom filed a $75 million mixed shelf registration Friday?
Human Genome Sciences
( HGSI):
The week's worst-performing stocks:
Surmodics
(SRDX) - Get Surmodics Inc Report
(-30%),
Epicept
( EPCT) (-28%),
Metabolix
(MBLX)
(-25%),
Angiotech Pharmaceuticals
( ANPI) (-21%) and
Repros Therapeutics
(RPRXD)
(-19%).
Cadence Pharmaceuticals
(CADX)
sold 11.5 million shares at $8, raising $86 million to fund commercial launch of Ofirmev, a hospital-based intravenous form of acetameniphan.
> > Bull or Bear? Vote in Our Poll
Athersys
(ATHX) - Get Athersys, Inc. Report
received FDA clearance to start phase II study of Multistem stem cell therapy for inflammatory bowel disease.
Arena Pharma
(ARNA) - Get Arena Pharmaceuticals, Inc. Report
:
'Marginal' Obesity Drug Now Unsafe?
Research abstracts for
American Society of Hematology
annual meeting were
.
Cerus
(CERS) - Get Cerus Corporation Report
priced 7.37 million stock units (stock and warrants) at $2.85 a unit, raising $20 million.
FDA cleared
Polymedix
(PYMX.OB)
to begin human clinical trials of antibiotic PMX-30063.
Osiris Therapeutics
(OSIR) - Get Osiris Therapeutics, Inc. Report
Drags Feet on U.S. Approval Filing
Dendreon
(DNDN)
filed for FDA approval of an expansion to its Provenge manufacturing plant in New Jersey, while the Centers for Medicare and Medicaid (CMS) released the technical assessment of Dendreon's Provenge ahead of next week's National Coverage Determination meeting.
Micromet
( MITI) sold 9.9 million shares at $7.30, raising $72 million.
This week's
:
Theratechnologies
(TH.TO)
, Arena Pharmaceuticals,
Amarin
(AMRN) - Get Amarin Corp. Plc Report
, and Osiris Therapeutics.
A
preview of next week's important regulatory meetings
facing Human Genome Sciences, Dendreon and
MELA Sciences
(MELA)
.
Human Genome: Benlysta FDA Panel Preview
Glaxo
(GSK) - Get GlaxoSmithKline Plc Report
Lawyer Indicted for Obstructing the FDA
(via Pharmalot)
European Drug Approval Agency Looking for new leader
(via invivo blog)
--Written by Adam Feuerstein in Boston.
>To contact the writer of this article, click here:
Adam Feuerstein
.
>To follow the writer on Twitter, go to
http://twitter.com/adamfeuerstein
.
>To submit a news tip, send an email to:
.
Adam Feuerstein writes regularly for TheStreet.com. In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet.com. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback;
to send him an email.
